A Review of Phase II Acute Heart Failure Syndromes Clinical Trials

Heart Failure Clinics

Volumn 7, Issue 4, 2011, Pages 441-450

  Pang, Peter S ^a   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute heart failure; Clinical trials; Phase 2

Indexed keywords

DOBUTAMINE; FUROSEMIDE; LEVOSIMENDAN; PLACEBO; ROLOFYLLINE; TEZOSENTAN; TOLVAPTAN;

ACUTE HEART FAILURE; CONGESTIVE HEART FAILURE; CONSENSUS; CONTINUOUS INFUSION; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HYPOTENSION; MEDICAL LITERATURE; MORTALITY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRAM DEVELOPMENT; REVIEW;

ACUTE DISEASE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYNDROME;

EID: 80052934149     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.06.002     Document Type: Review

References (53)

1. Cuffe M.S., Califf R.M., Adams K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541-1547.
2. Gheorghiade M., Konstam M.A., Burnett J.C., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007, 297(12):1332-1343.
3. Konstam M.A., Gheorghiade M., Burnett J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007, 297(12):1319-1331.
4. McMurray J.J., Teerlink J.R., Cotter G., et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS Randomized Controlled Trials. JAMA 2007, 298(17):2009-2019.
5. Mebazaa A., Nieminen M.S., Packer M., et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007, 297(17):1883-1891.
6. Sackner-Bernstein J.D., Kowalski M., Fox M., et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005, 293(15):1900-1905.
7. Sackner-Bernstein J.D., Skopicki H.A., Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111(12):1487-1491.
8. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002, 287(12):1531-1540. VMAC Investigators.
9. Gheorghiade M., Abraham W.T., Albert N.M., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006, 296(18):2217-2226.
10. Jencks S.F., Williams M.V., Coleman E.A. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009, 360(14):1418-1428.
11. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29(19):2388-2442.
12. Fang J., Mensah G.A., Croft J.B., et al. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 2008, 52(6):428-434.
13. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53(15):e1-e90.
14. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119(3):480-486.
15. Yancy C.W. Climbing the mountain of acute decompensated heart failure: the EVEREST Trials. JAMA 2007, 297(12):1374-1376.
16. Pang P.S., Cleland J.G., Teerlink J.R., et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 2008, 29(6):816-824.
17. Pang P.S., Konstam M.A., Krasa H.B., et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 2009, 30(18):2233-2240.
18. Mebazaa A., Pang P.S., Tavares M., et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J 2009, 31(7):832-841.
19. Blair J.E., Zannad F., Konstam M.A., et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol 2008, 52(20):1640-1648.
20. Felker G.M., Pang P.S., Adams K.F., et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 2010, 3(2):314-325.
21. Gheorghiade M., Zannad F., Sopko G., et al. Acute heart failure syndromes: current state and framework for future research. Circulation 2005, 112(25):3958-3968.
22. Gheorghiade M., Gattis W.A., Barbagelata A., et al. Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. Am Heart J 2003, 145(Suppl 2):S51-S54.
23. Udelson J.E., Orlandi C., Ouyang J., et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008, 52(19):1540-1545.
24. Goldsmith S.R., Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005, 46:1785-1791.
25. Gheorghiade M., Filippatos G., De Luca L., et al. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 2006, 119(12 Suppl 1):S3-S10.
26. Teerlink J.R. Overview of randomized clinical trials in acute heart failure syndromes. Am J Cardiol 2005, 96(6A):59G-67G.
27. Teerlink J.R., McMurray J.J., Bourge R.C., et al. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J 2005, 150(1):46-53.
28. Aronson D., Burger A.J. Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: role of endothelin. Pacing Clin Electrophysiol 2003, 26(3):703-710.
29. O'Connor C.M., Gattis W.A., Adams K.F., et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 2003, 41(9):1452-1457.
30. Cotter G., Kaluski E., Stangl K., et al. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail 2004, 6(5):601-609.
31. Teerlink J.R., Metra M., Felker G.M., et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009, 373(9673):1429-1439.
32. Cotter G., Dittrich H.C., Weatherley B.D., et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008, 14(8):631-640.
33. Teerlink J.R. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. Am Heart J 2003, 145(Suppl 2):S26-S33.
34. Gheorghiade M., Teerlink J.R., Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol 2005, 96(6A):68G-73G.
35. Slawsky M.T., Colucci W.S., Gottlieb S.S., et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000, 102(18):2222-2227.
36. Nieminen M.S., Akkila J., Hasenfuss G., et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000, 36(6):1903-1912.
37. Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002, 360(9328):196-202.
38. Moiseyev V.S., Poder P., Andrejevs N., et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002, 23(18):1422-1432.
39. Zairis M.N., Apostolatos C., Anastasiadis P., et al. 835-6 The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: results from the calcium sensitizer or inotrope or none in low output heart failure study (CASINO). J Am Coll Cardiol 2004, 43(5 Suppl 1):A206-A207.
40. Packer M., Colucci W.S., Fisher L. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE-1 study. J Card Fail 2003, 9:S61. [abstract].
41. Packer M. REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure [abstract]. Paper presented at: American Heart Association Scientific Sessions 2005 Late Breaking Clinical Trials II. Dallas, November 13-16, 2005.
42. Packer M. The Randomized multicenter EValuation of Intravenous leVosimendan Efficacy-2 (REVIVE-2) trial, Late-breaking Clinical Trials 2005, American Heart Association, Annual Scientific Session, Dallas (TX), p. 13-6.
43. Gottlieb S.S., Abraham W., Butler J., et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002, 8(3):136-141.
44. Smith G.L., Lichtman J.H., Bracken M.B., et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006, 47(10):1987-1996.
45. Smith G.L., Vaccarino V., Kosiborod M., et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?. J Card Fail 2003, 9(1):13-25.
46. Gottlieb S.S., Brater D.C., Thomas I., et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002, 105(11):1348-1353.
47. Gottlieb S.S., Skettino S.L., Wolff A., et al. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 2000, 35(1):56-59.
48. Givertz M.M., Massie B.M., Fields T.K., et al. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007, 50(16):1551-1560.
49. Dittrich H.C., Gupta D.K., Hack T.C., et al. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 2007, 13(8):609-617.
50. Weatherley B.D., Cotter G., Dittrich H.C., et al. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. J Card Fail 2010, 16(1):25-35.
51. Massie B.M., O'Connor C.M., Metra M., et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010, 363(15):1419-1428.
52. Torre-Amione G., Young J.B., Colucci W.S., et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003, 42(1):140-147.
53. Kaluski E., Kobrin I., Zimlichman R., et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 2003, 41(2):204-210.